Confirmatory Study of 17P vs Vehicle for Prevention of Preterm Birth in Women w/ Previous Spontaneous Preterm Delivery

Phase 3

Completed

Conditions: Preterm Birth

Interventions: Drug: Vehicle
Drug: Hydroxyprogesterone Caproate Injection (HPC), 250mg/mL

Registration Number: NCT01004029

Lead Sponsor: AMAG Pharmaceuticals, Inc.

Brief Summary: As part of the continuing effort to study the benefit and risks of 17P and preterm delivery, this study is designed as a multi-center, randomized, double-blind, vehicle-controlled clinical trial of 17P for the prevention of preterm birth prior to 35 weeks, 0 days of gestation in women with a singleton pregnancy, aged 18 years or older, with a previous singleton spontaneous preterm delivery. The study also includes a population pharmacokinetic (PK) substudy to assess the hydroxyprogesterone caproate (HPC) exposure-response relationship and the effect of body mass index (BMI) on the PK of 17P.

Detailed Description: One of the most significant risk factors for preterm birth is previous pregnancy history. Women who have had a prior preterm birth have a 2.5-fold greater risk than women with no prior history of preterm birth. Prophylactic methods for prevention of preterm birth, including tocolytic drugs, bed rest, and other interventions such as cerclage, have been shown in most studies to be ineffective. One of the preventive measures that has shown effectiveness in randomized trials is the use of progesterone agents.9,10 Progesterone has been shown to support gestation and to inhibit uterine activity.

Recruitment & Eligibility

Status: COMPLETED

Sex: Female

Target Recruitment: 1740

Inclusion Criteria

Each subject must meet the following criteria to be enrolled in this study:

Age ≥ 18 years.
Singleton gestation.
Project gestational age 16 weeks 0 days of gestation or more and less than or equal to 20 weeks 6 days of gestation at the time of randomization, based on clinical information and evaluation of the first ultrasound.
Documented history of a previous singleton spontaneous preterm delivery. Spontaneous preterm birth is defined as delivery from 20 weeks 0 days to 36 weeks 6 days of gestation following spontaneous preterm labor or pPROM. Where possible, the gestational age of the previous preterm birth (referred to as the qualifying delivery) should be determined as described in "Gestational Age Determination". If the gestational age at delivery is obtained directly from the medical record and more than one gestational age appears, the latest will be used. As a validation of the gestational age of the previous delivery, if the infant weighed more than 3300 grams (the birth weight 90th percentile for 36 weeks gestational age), this will not qualify as preterm. The previous preterm delivery cannot be an antepartum stillbirth.

Exclusion Criteria

Multifetal gestation.
Known major fetal anomaly or fetal demise. An ultrasound examination between 14 weeks 0 days through 20 weeks 3 days of gestation must be performed to rule out fetal anomalies.
Progesterone treatment in any form (i.e., vaginal, oral, intramuscular) during current pregnancy, other than micronized progesterone delivered orally or vaginally provided it is stopped at least 4 weeks prior to the first dose of study medication.
Heparin therapy during current pregnancy or history of thromboembolic disease.
Maternal medical/obstetrical complications including:
- Current or planned cerclage
- Hypertension requiring medication
- Seizure disorder
Subjects with a uterine anomaly (uterine didelphys or bicornate uterus). However, subjects with uterine fibroids are eligible for the study.
Unwillingness to comply with and complete the study.
A 14 weeks 0 days through 20 weeks 3 days of gestation ultrasound cannot be arranged before randomization.
Participation in an antenatal study in which the clinical status or intervention may influence gestational age at delivery.
Participation in this trial in a previous pregnancy. Women who were screened in a previous pregnancy, but not randomized, do not have to be excluded.
Known hypersensitivity to hydroxyprogesterone caproate or its components.
Have any significant medical disorder that, in the opinion of the investigator, would be a contraindication to the use of the drug including those listed in section 5.3.2 of the investigational brochure. Other examples to consider include uncontrolled diabetes, known HIV infection or renal dysfunction.
Have any significant medical disorder that, in the opinion of the investigator, would preclude accurate evaluation of the subject's condition or outcome in the study.

Study & Design

Study Type: INTERVENTIONAL

Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Vehicle	Vehicle	Castor Oil
Hydroxyprogesterone Caproate Injection (HPC), 250 mg/mL	Hydroxyprogesterone Caproate Injection (HPC), 250mg/mL	HPC 250 mg/mL in oil

Primary Outcome Measures

Name	Time	Method
Preterm Birth <35 Weeks Gestation	Up to 35 weeks	Determine if treatment with 17P reduces the rate of preterm birth \< 35 weeks, 0 days of gestation in women with a previous singleton spontaneous preterm delivery.
Neonatal Composite Index (NCI)	Until 28 days of life or discharge from the neonatal intensive care unit (NICU), whichever occurred later.	The composite index is defined as a liveborn neonate with any of the following occurring at any time during the birth hospitalization up through discharge from the NICU: neonatal death, grade 3 or 4 intraventricular hemorrhage, respiratory distress syndrome, bronchopulmonary dysplasia, necrotizing enterocolitis or proven sepsis.

Secondary Outcome Measures

Name	Time	Method
Fetal/Early Infant Death	Delivery from 16 weeks 0 days through 19 weeks 6 days of gestation; or neonatal death occurring in liveborns born at less than 24 weeks gestation; or stillbirth (antepartum or intrapartum death) from 20 weeks gestation through term).	Defined as spontaneous abortion/miscarriage (delivery from 16 weeks 0 days through 19 weeks 6 days of gestation) or neonatal death occurring in liveborns born at less than 24 weeks gestation or stillbirth (antepartum or intrapartum death from 20 weeks gestation through term), in the 17P group compared to the vehicle group
Preterm Birth Prior to 32 Weeks Gestation	Up to 32 weeks
Preterm Birth Prior to 37 Weeks Gestation	Up to 37 weeks
Stillbirths	20 weeks gestation until term	Defined as all stillbirths/fetal deaths/in utero fetal losses occurring from 20 weeks gestation until term.
Neonatal Deaths With ≥24 Weeks Gestational Age	Until 28 days of life or discharge from the NICU whichever occurred later.	Neonatal death (from minutes after birth until 28 days of life) occurring in liveborns born at 24 weeks gestation or greater

Trial Locations

Locations (103): Drug Research & Analysis Corporation
🇺🇸
Montgomery, Alabama, United States
Tucson Medical Center (Watching Over Mothers and Babies Foundation)
🇺🇸
Tucson, Arizona, United States
Grossmont Center for Clinical Research
🇺🇸
La Mesa, California, United States
Naval Medical Center San Diego - Department of Obstetrics and Gynecology
🇺🇸
San Diego, California, United States
Womens Health Specialists
🇺🇸
West Hills, California, United States
Women's Associates, P.C.
🇺🇸
Colorado Springs, Colorado, United States
Red Rocks OB/GYN - Physician's Research Options, LLC
🇺🇸
Lakewood, Colorado, United States
Visions Clinical Research
🇺🇸
Boynton Beach, Florida, United States
Palm Beach Obstetrics & Gynecology, PA (Altus Research)
🇺🇸
Lake Worth, Florida, United States
Global OB/GYN Centers
🇺🇸
Pembroke Pines, Florida, United States
Scroll for more (93 remaining)
Drug Research & Analysis Corporation
🇺🇸Montgomery, Alabama, United States